Realigning Merger Remedies with the Goals of Antitrust
The current focus on antitrust enforcement is supported by an important dialogue on evidence of declining competition in the US economy. We do not yet know the full extent to which rising concentration, slowing rates of start-ups and widening inequality gaps are the product of the lax antitrust enforcement that has prevailed in US for three decades. As this story continues to unfold, it remains clear that merger enforcement should be high on the antitrust agenda. The US Department of Justice (DOJ) and Federal Trade Commission (FTC) are in unique positions to learn from their past experience in merger enforcement, particularly with regard to the effectiveness of their remedies. This commentary highlights the importance of merger remedies in the broader debate over the role and goals of antitrust. It argues that a number of themes are converging to create an inflection point in remedies policy. This puts the spotlight on the series of very recent and controversial merger enforcement decisions under the Trump administration that are likely to have a strong and potentially detrimental influence on the policy trajectory surrounding remedies.
One theme is a clearer emphasis on the role of antitrust in protecting competition and promoting consumer welfare through the process and goals of law enforcement. Remedies policy should be aligned with the mission and workings of antitrust, namely through the crafting of effective remedies that deter anticompetitive conduct. A second development is the expanding body of evidence on the success and failure of past merger remedies. Merger ‘retrospectives’ and agency guidance reveal the limitations of both conduct (i.e., behavioural) and structural fixes. This evidence and experience should be reflected in remedies policy.
A third theme is the expanding number of cases where the agencies blocked or forced the abandonment of a merger because an effective remedy could not be found. This highlights the fact that the government’s move to block a merger is in itself an effective remedy, highlighted by the more frequently encountered problem of ‘too big to fix’. We begin with some context for revisiting merger remedies by summarising the major elements of the current debate over antitrust and lessons learned from sector regulation, where remedies are also important. The analysis then moves to the three themes described above: merger remedies as the product of the law enforcement process; growing agency evidence and experience with remedies; and the limitations of remedies in light of more recent cases.
Antitrust in context – framing the broader debate around merger remedies
The changing ideological spectrum
Policy surrounding merger remedies is embedded in the broader current debate over the appropriate role for antitrust enforcement in protecting competition and consumer welfare, promoting economic growth, facilitating equity in the distribution of wealth and income, and spurring innovation. The varying answers to these questions have stretched the ideological spectrum around antitrust in the US, bringing into focus three current perspectives: conservative, populist and progressive.
Conservatives generally argue that antitrust enforcement should take a light hand. They give considerable deference to claims that mergers and some forms of restrictive conduct promote cost savings, quality control, consumer benefits and other efficiencies. Conservative ideology uses a broad lens through which to view the effects of potential or actual competitive abuses. For example, mergers or conduct that purportedly generate efficiencies are believed to be pro-competitive, even if they harm consumers through higher prices, lower quality or less innovation.
Conservative thinking has strongly influenced merger remedies. Numerous large horizontal mergers in highly concentrated markets have been allowed, with and without remedies, even though such transactions were presumptively illegal under Section 7 of the Clayton Act. Conservative thinking is also evident in vertical merger policy where the agencies have given significant weight to the complex and often difficult to prove efficiencies claims arising from vertical integration. As discussed later, this has resulted in the use of conduct remedies in a number of high-profile vertical mergers.
In the middle of the spectrum is progressivism, which encourages vigorous enforcement under the full scope of the existing law and the prevailing consumer welfare standard. Progressives highlight the ability of the consumer welfare standard to address both price and non-price dimensions of competition such as quality and innovation. Any source of market power (e.g., buyer or seller) is also reachable under the standard, which allows antitrust to evaluate concerns in output and input markets, including labour. The progressive view also acknowledges that antitrust enforcement is an important tool in a ‘toolkit’ that includes other policies for promoting competition and protecting consumers.
On the question of merger remedies, progressive thinking recognises the limitations of regulatory-style conduct fixes and structural remedies that target specific assets, as opposed to lines of business. In promoting vigorous enforcement, progressives support the ‘structural presumption’ that a merger in a highly concentrated market will almost certainly harm competition and consumers. The most effective remedy for mergers in such cases may therefore be for the government to move to block the merger.
At the left end of the spectrum is a neo-populist ideology focused generally on the inadequacy of the antitrust laws and consumer welfare standard. Populists are relatively new to the debate and have a major focus on monopoly and the online technology companies. They have advocated recently for breaking up some of the large online technology companies using antitrust as a major tool.
Relative to progressivism, conservatism has arguably resulted in long-term under-enforcement of the antitrust laws, whereas populism seemingly seeks to use the antitrust laws to achieve broader policy goals than for which they were designed.
Learning from the antitrust regulation partnership
The debate over merger remedies is informed by the role of antitrust as part of the broader toolkit of policy instruments that promote competition and consumer welfare. This includes trade, regulation, labour, consumer protection and privacy, education, and small business policy. There is a particularly important and established partnership between antitrust enforcement and sector regulation that can usefully inform remedies policy. Each works in different ways – antitrust through law enforcement, and sector regulators (as administrative agencies) through promulgating and implementing standards and rules that govern how the underlying laws will be enforced.
Antitrust and regulation often work in tandem to reach competitive issues that the other cannot address. For example, the Federal Energy Regulatory Commission can find strategic withholding of generation capacity for the purpose of driving up electricity prices a violation of ‘just and reasonable’ rates. Capacity withholding that does not involve exclusion of rivals or an anticompetitive agreement, however, is not reachable under the antitrust laws. Antitrust and regulation also employ different standards, which can capture a variety of adverse effects. Antitrust focuses exclusively on promoting competition and consumer welfare. Regulation also pursues harm to competition, but also other objectives under a public interest standard, including reliability of service, safety, diversity (e.g., media) and even employment. The Federal Communication Commission’s now rescinded net neutrality rules reflected the goals of a broader public interest agenda to promote an open internet, competition, and diversity in content and distribution.
Antitrust and sector regulators can diverge significantly on merger remedies. Regulation almost universally employs conduct remedies that encompass complex rules and requirements, often involving long-term commitments that necessitate ongoing interaction between the regulator and regulated firm. As administrative agencies, sector regulators are well suited to oversight and compliance enforcement, which may allow them to monitor markets and shape future agency policy. But such remedies also open the door to regulatory capture and market distortions from ‘second-best’ fixes. In contrast, the antitrust agencies have historically favoured structural remedies. These involve a one-time fix through a permanent reduction in a firm’s incentive or ability to exercise market power. They also place significantly less burden on the agencies and courts, which are not well suited to monitoring and compliance.
Merger remedies and deterrence value
Antitrust remedies deter illegal anticompetitive conduct
The antitrust agencies enforce the antitrust laws through a process of discovery, investigation and deterrence of violations. The agencies have a number of remedies at hand, including injunctions and disgorgement in civil cases, fines and incarceration in criminal cases brought by the DOJ, and civil penalties for decree violations. Enforcement against anticompetitive agreements (e.g., cartels) through Section 1 of the Sherman Act is perhaps the best illustration of antitrust as law enforcement, where the optimal deterrence value of penalties is a central focus.
A small but important case illustrates the concept of antitrust as law enforcement. The DOJ’s settlement in Gunnison Energy and SG Interests Inc levied minimal damages on two companies for rigging bids for natural gas leases on public land in Colorado. Dozens of public comments highlighted the inadequacy of the penalty. Judge Matsch agreed. He denied a motion for entry of a final judgment under the Antitrust Policies and Procedures Act (the Tunney Act), noting, ‘There is no basis for saying that the approval of these settlements would act as a deterrence [sic] to these defendants and others in the industry . . . .’
Mapping the deterrence value of remedies to merger enforcement
The role of antitrust enforcement in deterring anticompetitive behaviour maps directly over to merger remedies, at least as to ‘specific deterrence’ or deterring future violations by a defendant. Once an enforcement action for a violation under Section 7 has been brought, an effective remedy must follow. The DOJ’s 2011 Policy Guide to Merger Remedies (guidelines) state that a remedy ‘must effectively preserve competition in the relevant market’, which should be ‘understood to include the concept of restoring competition or enhancing consumer welfare’. In September 2018, the Assistant Attorney General for antitrust at the DOJ withdrew the 2011 guidelines and placed the 2004 Policy Guide to Merger Remedies back into effect. However, the goal of crafting effective remedies to preserve competition remains the same in the 2004 and 2011 guidelines. A remedy must therefore address the elements through which consumer welfare can be diminished by an illegal merger, including adverse price effects and other non-price dimensions of competition, such as reduced quality and innovation.
As an integral part of law enforcement, an effective remedy should deter anticompetitive behaviour after a merger is consummated. However, the major differences among merger remedies raise questions about whether they actually deter illegal behaviour. For example, in some cases, the most effective remedy is the agency’s request for a permanent injunction to block a merger. Short of this, the agencies have used behavioural and structural remedies to address competitive concerns. But in many cases, such remedies do not align closely with the goal of deterrence, revealing a divergence from antitrust as law enforcement.
Federal judges have expressed reservations about the deterrence value of remedies in only a limited number of Tunney Act reviews. Otherwise, consent orders have been routinely approved. The limited historical role of the Tunney Act review process highlights the notion that judicial review of a consent order under the Tunney Act should not be the first line of defence to a merger remedy that falls afield of the goal of law enforcement. Effective remedies that deter anticompetitive conduct should be considered as a major policy goal. The former Assistant Attorney General for Antitrust under the Obama administration, William Baer, explained, ‘Getting remedies right is central to merger enforcement policy.’
Realigning merger remedies with the goals of antitrust
The tension in agency remedies policy
Agency policy regarding the goals of merger remedies has remained consistent over time.
For example, the 2011 DOJ remedies guidelines explain, ‘The touchstone principle for the Division in analyzing remedies is that a successful merger remedy must effectively preserve competition in the relevant market.’ The guidelines note that remedies include blocking a merger or settling to avoid a contested litigation. But when a merger is allowed to proceed with a remedy, consumer welfare must be protected. This approach to merger remedies is consistent with antitrust as law enforcement, namely to deter future anticompetitive behaviour.
While the DOJ and FTC have consistently articulated the goals of merger remedies, the agencies’ policies governing how remedies achieve them have changed over time. This reflects an ongoing tension in the balancing of theory and practice. For example, the DOJ’s 2004 remedies guidelines stated that structural remedies were preferred to behavioural fixes. Those guidelines state: ‘They [structural remedies] are relatively clean and certain, and generally avoid costly government entanglement in the market. A carefully crafted divestiture decree is “simple, relatively easy to administer, and sure” to preserve competition.’
Between 2009 and 2011, however, the DOJ challenged a number of high-profile vertical merger cases and largely settled them with conduct remedies. These included Comcast/NBCU, Live Nation/Ticketmaster and Google/ITA. In 2011, the DOJ rewrote the remedies guidelines to put less emphasis on structural and more emphasis on conduct remedies. Presumably this codified the agency’s approach to vertical merger enforcement at the time, which gave considerable deference to efficiencies claims arising from vertical integration. Even so, the 2011 remedies guidelines state that merger-related efficiencies are of secondary importance to restoring competition, explaining that a remedy ‘preserve[s] the efficiencies created by a merger, to the extent possible, without compromising the benefits that result from maintaining competitive markets’.
The growing divide between conduct and other remedies
The DOJ’s policy transition in the 2011 remedies guidelines raised many questions that remain in force, regardless of which version of the remedies guidelines the DOJ follows. For example, the behavioural remedies contained in numerous consent orders are well known to be fraught with problems that directly affect their deterrence value. They articulate prohibited, permitted and required conduct – requirements that do nothing to change the merged firm’s incentives to exercise market power and encourage circumvention of the rules. Conduct remedies also depend on smaller market participants, under the weak protection of anti-retaliation provisions, coming forth to lodge complaints about non-compliance.
Conduct remedies are thus oriented around a ‘design’ standard, namely compliance with the requirements of the remedy. This stands in stark contrast to structural remedies that are shaped around a ‘performance’ standard, or an ‘obligation in terms of ultimate goals that must be achieved’. Conduct remedies thus carry a higher risk of failure, a risk that is more likely to be shouldered by consumers, not the merging parties. One reason for this is that conduct remedies require ongoing monitoring and enforcement by the agencies and the courts, which are not, as noted earlier, well suited to act as regulators.
For example, in the Tunney Act review in Comcast/NBCU, Judge Leon expressed misgivings about the effectiveness of the proposed behavioural remedy, stating: ‘because of the way the Final Judgment is structured, the Government’s ability to “enforce” the Final Judgment, and, frankly, this Court’s ability to oversee it, are, to say the least, limited’. Judge Leon went on to say that ‘the Government, at the public hearing, freely admitted that “[w]e can’t enforce this decree.”’ In the merger of ABInBev/Miller Coors, numerous parties filed amicus briefs as part of the Tunney Act review process. They emphasised the drawbacks of the conduct remedy in the consent order, which is designed to constrain ABInBev/Miller Coors’ powerful incentives to favour the distribution of its own products over smaller rivals. These cases reflect the concern that an unenforceable or hard-to-monitor consent order has questionable deterrence value.
Because structural remedies permanently change the merged firm’s ability or incentive to exercise market power they require less, if any, ongoing monitoring and enforcement after a successful transition of divested assets to a viable buyer. But some structural remedies are not bulletproof either. For example, the FTC has experienced problems with some structural remedies involving divestitures of targeted assets. In the merger of retail grocers Safeway and Albertsons, the FTC-approved sale of almost 150 stores to a regional west coast grocer (Haggen) led to the failure and shuttering of the divested stores only a few months later. In Hertz/Dollar Thrifty, the buyer of the divested assets (Advantage Rent-a-Car) filed for bankruptcy soon after the sale. And despite divestitures in the UnitedHealth/Sierra and the Aetna/Prudential mergers, analysts have documented post-merger premium increases.
Incorporating agency experience and learning into policy
Lawmakers have not been shy about highlighting instances in which merger remedies have been ineffective. At a December 2017 Senate Judiciary Committee hearing on the consumer welfare standard, for example, Senator Richard Blumenthal highlighted concerns over the Comcast/NBCU consent order, suggesting reopening the investigation to consider extending the behavioural conditions or perhaps unwinding the transaction. Senator Blumenthal’s statement highlights the importance of agency learning as a vital component of rebalancing the goals and effectiveness of merger remedies.
Merger retrospectives, or studies of post-merger outcomes, are being performed with more frequency than ever before. They demonstrate that in many cases consummated mergers have harmed consumer welfare through higher prices. And empirical ‘meta-analysis’ of a large number of merger retrospectives demonstrates that divestitures often fail to resolve competitive problems. These are needed tools for improving merger enforcement, including the effectiveness and deterrence value of merger remedies. Proposed legislation by Senator Amy Klobuchar would formalise the needed collection and study of post-merger data to improve the effectiveness of merger remedies.
To the agencies’ credit, both the DOJ and FTC appear receptive to periodically studying their remedies and updating their guidance. The FTC has performed two major studies of its divestiture remedies – one in 1999 and an update in 2017. The latter study revealed important observations, including that targeted asset divestitures are much less effective than line of business divestitures. The report noted ‘all of the divestitures involving an ongoing business succeeded. Divestitures of limited packages of assets in horizontal, non-consummated mergers fared less well . . . .’
As discussed above, a number of failed FTC merger remedies have revealed the limitations of structural remedies. It remains to be seen, however, how the implications of the FTC’s recent divestiture study are incorporated into future enforcement or how any change in DOJ remedies policy will be reflected in agency guidance. Will there be more attempts to block illegal mergers and increased reliance on structural remedies? Will we see more line-of-business divestitures, as opposed to sales of targeted assets, in FTC enforcement actions where remedies are taken? If the DOJ’s challenge to the AT&T/Time Warner acquisition is any indication, the answer appears to be yes.
Testing the limits of merger remedies: the problem of ‘too big to fix’
A number of recent, large horizontal mergers have been successfully blocked by the agencies or abandoned in the face of government opposition. These include: Staples/Office Depot, Sysco/US Foods, John Deere/Precision Planting, GE/Electrolux, Applied Materials/Tokyo Electron, Halliburton/Baker Hughes and Anthem/Cigna. These deals share a number of characteristics: highly concentrated markets, poor prospects for new entry, the absence of viable buyers of potential divestiture assets, and complex business organisations. They illustrate that some deals really are ‘too big to fix’ and should be blocked outright.
Notwithstanding the fact that a merger in a highly concentrated market is presumptively illegal, resource-constrained enforcers are often enticed into fixes proposed by the parties ‘up front’ as part of the merger deal. They should resist this pressure to settle.
A government move to block a merger is in itself a remedy. For a number of reasons, it is often the one with the most deterrence value. First, viable buyers of divestiture assets may be impossible to find, particularly in highly concentrated markets. Several cases illustrate this problem, including the Safeway/Albertsons and the Hertz/Dollar Thrifty mergers, where buyers failed to maintain the assets and subsequently exited the market. In mergers that were successfully blocked by the government, including Sysco/US Foods, Staples/Office Depot and Halliburton/Baker Hughes, viable buyers of possible divestiture assets did not exist.
The lessons from the foregoing cases are clear. Divestitures to incumbents in the market would essentially be a game of ‘musical chairs’, or shifting assets from one market incumbent to another. This risks maintaining, or even increasing, post-merger levels of concentration. Divestitures to a potential market entrant would more effectively dilute higher market concentration or tighter vertical integration that follows large mergers. But such a buyer would need to function independently (without the help of the merging parties), successfully maintain the assets and quickly reinject the competition lost by the merger. Such entrants may be hard to find, or even non-existent.
However, recent experience under the Trump administration’s antitrust chiefs signals significant slippage in merger enforcement more generally, and remedies policy in particular. For example, there is no better merger retrospective than action taken by an agency to address the violation of remedies in a consent order. In early 2020, the DOJ moved to amend the original consent order in the Live Nation/Ticketmaster merger, which included prohibitions on anticompetitive conduct and retaliation against concert venue owners. A DOJ investigation revealed persistent violations of the decree since it went into effect in 2010 and the motion to modify the consent decree includes accounts from six anonymous venue operators describing threats, conditions and retaliation designed to force venue operators into contracting with Ticketmaster as their primary ticketing service. In response, rather than pursuing a more effective structural remedy, the DOJ only sought to extend the original decree that the company ably violated for the past decade, by another five and a half years.
The FTC recently approved the merger of Staples and Essendant, the largest vertically integrated US reseller of office products (and one of two retail office supply superstores) and largest US wholesale distributor of office products, respectively. The FTC’s consent order requires the companies to establish a firewall separating Staples’ business-to-business sales operations from Essendant’s wholesale business to restrict Staples’ access to the Essendant’s customers’ commercially sensitive information. Firewalls are perhaps the more troubling form of behavioural remedy in that they do nothing to reduce the firm’s incentive to exercise market power. Incentives to ‘work around’ firewalls are strong and violations of the consent order would only be detected by significant and ongoing monitoring of the merged firm’s internal operations.
Likewise, in the merger of wireless carriers Sprint and T-Mobile, rather than blocking a harmful 4-3 merger, the DOJ took a remedy. The package of divestitures and behavioural access requirements would be handed off to a satellite television provider, Dish Network, which has no experience in the wireless markets. The dubious viability of Dish Network as a buyer in this case will be closely monitored should the merger survive judicial review, and if a parallel case to block the merger brought by the states does not succeed. These decisions stand in contrast to early messaging from the current Assistant Attorney General for Antitrust, Makan Delrahim, who noted of conduct remedies, ‘[i]nstead of protecting the competition that might be lost in an unlawful merger, a behavioral remedy supplants competition with regulation.’
Second, the complexity of a remedy is likely to correlate with the complexity of a merger. A potential buyer will inherit a diverse package of assets from players that are deeply entrenched in the market. This often involves significant involvement in R&D and distribution, in addition to production and marketing. Structural remedies in such situations are often accompanied by conduct remedies such as limited-term supply agreements to increase the chances of a successful transition from the merged company to the buyer. Remedies may also include licensing and access provisions to ensure that the buyer has continued access to technology or distribution controlled by the merged company.
A complex remedy is compounded by other problems that may be overlooked by enforcers. For example, managers must simultaneously integrate two large business ecosystems post-merger, while simultaneously undoing key businesses by spinning off assets. Moreover, they must concurrently make good on their promises to deliver cost savings and consumer benefits. Completing these tasks presses on the bounds of managerial competency at the same time they create significant changes that are likely to affect profit incentives, relationships between affiliates and other key operational factors. Collectively, these factors affect post-merger operations, conduct and strategy.
There is a commensurately higher risk that a complex merger remedy will not be executed successfully. The government’s experience in Comcast/NBCU, Live Nation/Ticketmaster and even in ABInBev/Miller Coors highlights this risk. The recent and historically large settlement in the ‘too big to fix’ merger of Monsanto and Bayer raises the spectre of significant execution risk. The settlement notably includes potentially difficult to implement conditions that appear designed to correct possible inadequacies in the remedy that might become apparent post-merger. Complex remedies are therefore likely to conflict directly with the government’s requirement that an effective remedy preserve competition and protect consumers.
This commentary has taken on the question of merger remedies at a time when concerns over declining competition in the United States have intensified the debate over the role of antitrust enforcement. It recognises the importance of antitrust as law enforcement. By extension, effective merger remedies should achieve the goals of law enforcement, namely to fully restore competition and deter any anticompetitive post-merger conduct.
A growing body of evidence points in the direction of needed change in remedies policy. This includes recognising problems with conduct remedies that focus on compliance and not on performance. Likewise, structural remedies should be revisited in ways that recognise the greater effectiveness of line of business divestitures, rather than targeted assets. Finally, when the government is unable to fashion an effective remedy that will deter anticompetitive post-merger conduct, the only effective remedy is to move to block the merger. Of course, the agencies need resources that will enable them to resist pressures to settle and go to court, if necessary, to protect competition and consumers.
1 Diana L Moss is president of the American Antitrust Institute. This chapter was written prior to the release of the Department of Justice’s new Merger Remedies Guidelines. An updated version of this chapter will be available online.
2 See A National Competition Policy: Unpacking the Problem of Declining Competition and Setting Priorities Moving Forward, American Antitrust Institute (28 September 2016), www.antitrustinstitute.org/wp-content/uploads/2018/08/AAINatlCompPolicy-1.pdf. See also Council of Economic Advisers, Benefits of Competition and Indicators of Market Power (April 2016), https://obamawhitehouse.archives.gov/sites/default/files/page/files/20160414_cea_competition_issue_brief.pdf.
3 For a full discussion of using merger remedies to promote general deterrence, see Steven C Salop, ‘Merger Settlement and Enforcement Policy for Optimal Deterrence and Maximum Welfare’, 81 Fordham L Rev 2647 (2013).
4 The conservative view is rooted in Chicago School thinking, which interprets the consumer welfare standard more as a total welfare standard, under which potential violations are evaluated on the basis of their effect on the totality of consumer and producer surplus.
5 Note that merger-related efficiencies can include cost savings or consumer benefits, or both. The latter are particularly difficult to substantiate as merger-specific and cognisable but have nonetheless been accepted by the agencies in numerous merger proceedings, particularly airlines.
6 See, e.g., The Consumer Welfare Standard in Antitrust: Outdated or a Harbor in a Sea of Doubt? Hearing Before the United States Senate Committee on the Judiciary Subcommittee on Antitrust, Competition and Consumer Rights, 115th Cong (2017) (statement of Diana L Moss, President, American Antitrust Institute), www.antitrustinstitute.org/wp-content/uploads/2018/08/Moss_SJC-Sub-comm-Hearing_Consumer-Welfare_12.13.17.pdf.
7 The differences between antitrust and regulation are significant, procedurally and substantively. See e.g., Diana L Moss, ‘Antitrust Versus Regulatory Merger Review: The Case of Electricity’, 32 Rev Ind Org 32 241 (2008).
8 This was the root problem during the California energy crisis of 1999-2000. See, e.g., Attorney General Bill Lockyer, Attorney General’s Energy White Paper: A Law Enforcement Perspective on the California Energy Crisis (2004), https://oag.ca.gov/sites/all/files/agweb/pdfs/antitrust/publications/energywhitepaper.pdf. See also 16 US Section 791a (2018).
9 Protecting and Promoting the Open Internet, 80 Fed Reg 19,738 (13 April 2015). In contrast, antitrust cannot police restrictive conduct involving internet access until after it occurs. And even then, the subtlety of some forms of exclusion might fall outside the ambit of antitrust. See, e.g., American Antitrust Institute, Repeal of Network Neutrality Eliminates Important Antitrust-Regulation Partnership, Deprives Competition and Consumers of Needed Safeguards (22 December 2017), www.antitrustinstitute.org/wp-content/uploads/2018/08/AAI_Net-Neutrality-Repeal-Comm_F.pdf.
10 See, e.g., Ohio Edison Co., et al., 81 F.E.R.C., Paragraph 61,110 (1997). The Commission’s policy in the 1990s generally required that merging utilities open their transmission systems to access by rivals.
11 See, e.g., R G Lipsey and Kelvin Lancaster, ‘The General Theory of Second Best’, 24 Rev Econ Stud 11 (1956).
12 15 USC Section 16(e)(1) (2018).
13 United States v. SG Interests I Ltd, No. 12-cv-00395-RPM, 2012 WL 6196131, at *6 (D. Colo. 12 December 2012).
14 Footnote 3.
17 15 USC Section 16(b)–(h). See, e.g., United States v. Comcast Corp, 808 F Supp 2d 145, 149 (D.D.C. 2011). See also United States v. CVS Health and Aetna Inc., United States’ Motion To Clarify And Amend The Court’s Planned Tunney Act Procedure, Case No. 1:18-cv-02340-RJL (D.D.C. 19 April 2019). The judge in this case took the unusual step of calling a hearing to consider the remedy proposed by the government to address horizontal concerns but also vertical concerns that were not identified in the complaint.
18 Acting Associate Attorney General Bill Baer Delivers Remarks at American Antitrust Institute’s 17th Annual Conference (16 June 2016), www.justice.gov/opa/speech/acting-associate-attorney-general-bill-baer-delivers-remarks-american-antitrust-institute.
20 id. at 4.
21 US Dep’t of Justice, Antitrust Division Policy Guide to Merger Remedies, 7–8 (October 2004) (quoting United States v. E I du Pont de Nemours & Co, 366 US 316, 331 (1961)), www.justice.gov/atr/page/file/1175136/download.
22 See [Proposed] Final Judgment at Sections IV-VI, United States v. Comcast Corp, No. 1:11-cv-00106 (D.D.C. 31 January 2011), www.justice.gov/atr/case-document/proposed-final-judgment-76; [Proposed] Final Judgment, United States v. Ticketmaster Entm’t Inc, No. 1:10-cv-00139 (D.D.C. 29 June 2010), www.justice.gov/atr/case-document/proposed-final-judgment-248; [Proposed] Final Judgment, United States v. Google Inc, No. 1:11-cv-00688 (D.D.C. 8 April 2011), www.justice.gov/atr/case-document/file/497661/download.
23 US Dep’t of Justice, footnote 15, at 4 (emphasis added).
24 See John E Kwoka and Diana L Moss, ‘Behavioral Merger Remedies: Evaluation and Implications for Antitrust Enforcement’, 57 Antitrust Bull 979, 994, 1010 (2012). See also, John E Kwoka Jr, ‘Does Merger Control Work? A Retrospective on Enforcement Policy, Remedies, and Outcomes’, 78 Antitrust L J 619, 636 (2013).
25 See, e.g., Steven C Salop, ‘Modifying Merger Consent Decrees to Improve Merger Enforcement Policy’, 31 Antitrust 15 (2016).
26 See, e.g., Bill Baer, Responses of Assistant Attorney General Bill Baer to Questions Submitted for the Record Senate Judiciary Committee Subcommittee on Antitrust, Competition Policy, and Consumer Rights Hearing: ‘Oversight of the Enforcement of the Antitrust Laws’ (9 March 2016), www.judiciary.senate.gov/imo/media/doc/Baer%20Responses%20to%20QFRs.pdf; D Bruce Hoffman, Acting Director, Bureau of Competition, US Fed Trade Comm’n, It Only Takes Two to Tango: Reflections on Six Months at the FTC, 6–7 (2 February 2018), www.ftc.gov/system/files/documents/public_statements/1318363/hoffman_gcr_live_feb_2018_final.pdf.
27 United States v. Comcast Corp, 808 F Supp 2d 145, 149 (D.D.C. 2011).
28 id. (brackets in original).
29 ‘Court Review of ABI-SABMiller Merger Complete, Judge Signs Modified Final Judgment’, Alcohol L Rev (24 October 2018), http://alcohollawreview.com/justice-department-clear-abinbev-purchase-of-sabmiller-with-conditions/.
30 Modified Final Judgment, U.S. v. Anheuser-Busch InBev SA/NV and SABMiller, No. 1L16-cv-01483-EGS (D.D.C. 22 October 2018).
31 Press Release, Fed Trade Comm’n, FTC Requires Albertsons and Safeway to Sell 168 Stores as a Condition of Merger (27 January 2015), www.ftc.gov/news-events/press-releases/2015/01/ftc-requires-albertsons-safeway-sell-168-stores-condition-merger; Brent Kendall, ‘Haggen Struggles After Trying to Digest Albertsons Stores’, Wall St J (9 October 2015), www.wsj.com/articles/haggen-struggles-after-trying-to-digest-albertsons-stores-1444410394.
32 David McLaughlin, Mark Clothier and Sara Forden, ‘Hertz’ Spinoff of Advantage Rent A Car Was Doomed From the Start Says Insider’, Bloomberg (13 November 2013), https://skift.com/2013/11/30/hertz-spinoff-of-advantage-rent-a-car-was-doomed-from-the-start-says-insider/.
33 See, e.g., Jose R Guardado, David W Emmons and Carol K Kane, ‘The Price Effects of a Large Merger of Health Insurers: A Case Study of UnitedHealth-Sierra’, 1 Health Mgmt Pol’y 16 (2013); Leemore Dafny, Mark Dugga and Subramaniam Ramanaraynan, ‘Paying a Premium on your Premium? Consolidation in the US Health Insurance Industry’, 102 Am Econ Rev 1161 (2012).
34 See Ted Johnson, ‘Senator Asks DOJ to Take Another Look at Comcast-NBCUniversal Merger’, Variety (13 December 2017), www.variety.com/2017/politics/news/comcast-nbc-universal-deal-richard-blumenthal-1202639853/.
35 See, e.g., John Kwoka, ‘The Structural Presumption and the Safe Harbor in Merger Review: False Positives or Unwarranted Concerns?’ 81 Antitrust L J 837, 860–61 (2017). See also, John Kwoka, Mergers, Merger Control, and Remedies: A Retrospective Analysis of US Policy (2015). See also, e.g., Orley C Ashenfelter, Daniel S Hosken and Matthew C Weinberg, ‘The Price Effects of a Large Merger of Manufacturers: A Case Study of Maytag-Whirlpool’, Working Paper 17476, National Bureau of Economic Research (October 2011), www.nber.org/papers/w17476.pdf (finding price increases for dishwashers and relatively large price increases for clothes dryers, but no price effects for refrigerators or clothes washers); and Nathan H Miller and Matthew C Weinberg, ‘Mergers Facilitate Tacit Collusion: Empirical Evidence from the US Brewing Industry’ (25 March 2015) (finding that while the Miller/Coors joint venture resulted in merger-specific cost reductions, average retail prices increased post-consummation, likely because of tacit collusion).
36 Kwoka, footnote 35.
37 Merger Enforcement Improvement Act, S. 1811, 115th Congress Section 3 (2017).
38 FTC’s Merger Remedies 2006–2012, A Report of the Bureaus of Competition and Economics (January 2017), www.ftc.gov/system/files/documents/reports/ftcs-merger-remedies-2006-2012-report-bureaus-competition-economics/p143100_ftc_merger_remedies_2006-2012.pdf; A Study of the Commission’s Divestiture Process, Bureau of Competition (August 1999), www.ftc.gov/sites/default/files/attachments/merger-review/divestiture.pdf.
39 id., at 1.
40 See Press Release, Fed Trade Comm’n, After Staples and Office Depot Abandon Proposed Merger FTC Dismisses Case from Administrative Trial Process (19 May 2016), www.ftc.gov/news-events/press-releases/2016/05/after-staples-office-depot-abandon-proposed-merger-ftc-dismisses; Press Release, Fed Trade Comm’n, Statement of FTC Bureau of Competition Director Debbie Feinstein on Sysco and U.S. Foods’ Abandonment of Their Proposed Merger (29 June 2015), www.ftc.gov/news-events/press-releases/2015/06/statement-ftc-bureau-competition-director-debbie-feinstein-sysco; Complaint, United States v. Deere & Co, No. 1:16-cv-08515, at 16 and 18 (ND Ill 31 August 2016), www.justice.gov/opa/file/889071/download; Press Release, US Dep’t of Justice, Electrolux and General Electric Abandon Anticompetitive Appliance Transaction After Four-Week Trial (7 December 2015), www.justice.gov/opa/pr/electrolux-and-general-electric-abandon-anticompetitive-appliance-transaction-after-four-week; Press Release, US Dep’t of Justice, Applied Materials Inc. and Tokyo Electron Ltd. Abandon Merger Plans After Justice Department Rejected Their Proposed Remedy (27 April 2015), www.justice.gov/opa/pr/applied-materials-inc-and-tokyo-electron-ltd-abandon-merger-plans-after-justice-department; Complaint at 2, 30, 32, 36, United States v. Halliburton Co, No. 1:16-cv-00233-UNA (D. Del. 6 April 2016), www.justice.gov/opa/file/838651/download; Complaint at 25, United States v. Anthem Inc, No. 1:16-cv-01493 (D.D.C. 21 July 2016), www.justice.gov/atr/file/903111/download; see also, United States v. Anthem Inc, No. 17-5024, at 12–13 (D.C. Cir. 28 April 2017), www.justice.gov/atr/case-document/file/971316/download.
41 United States v. Ticketmaster Entertainment, Inc. and Live Nation Entertainment Inc., Motion To Modify Final Judgment and Enter Amended Final Judgment, Case No. 1:10-cv-00139-RMC (D.D.C. 8 Jan 2020) and United States v. Ticketmaster Entertainment, Inc. and Live Nation Entertainment Inc., Amended Final Judgment, Case No. 1:10-cv-00139-RMC (D.D.C. 28 Jan 2020).
43 Sycamore Partners II L.P., Staples Inc., and Essendant, Inc., Federal Trade Commission, Decision, Docket No. C-4667 (25 January 2019), www.ftc.gov/system/files/documents/cases/1810180_staples_essendant_do_and_apps_a-g-redacted_public_version.pdf.
44 United States of America v. Deutsche Telekom Ag, T-Mobile Us, Inc., Softbank Group Corp., Sprint Corporation, and Dish Network Corporation, Proposed Final Judgment, Case 1:19-cv-02232 (D.D.C. 26 July 2019), www.justice.gov/opa/press-release/file/1187706/download.
45 Makan Delrahim, Asst Att’y Gen, Dep’t of Justice, Antitrust Div, Keynote Address at American Bar Association’s Antitrust Fall Forum (16 November 2017), www.justice.gov/opa/speech/assistant-attorney-general-makan-delrahim-delivers-keynote-address-american-bar.
46 See, e.g., Letter from American Antitrust Institute, Food & Water Watch, and National Farmers Union to the US Department of Justice Re: Proposed Merger of Monsanto and Bayer (26 July 2017), www.antitrustinstitute.org/wp-content/uploads/2018/08/White-Paper_Monsanto-Bayer_7.26.17_0.pdf. See also Letter from American Antitrust Institute, Food & Water Watch, and National Farmers Union to the US Department of Justice Re: Monsanto-Bayer Merger: Competitive Concerns Surrounding Traits-Seeds-Chemicals Platforms, Digital Farming, and Farm Data (3 October 2017), www.antitrustinstitute.org/wp-content/uploads/2018/08/AAI-FWW-NFU_MON-BAY-addendum.pdf.
47 See Competitive Impact Statement at 17 and 18, US v. Bayer AG, Monsanto Company and BASF SE, Case 1:18-cv-01241 (D.C. Cir. 29 May 2018), www.justice.gov/opa/press-release/file/1066651/download.